ChemoTech receives an order for an IQWave™ D-EECT from Baypointe Hospital in the Philippines
Baypointe has today signed an order for an IQWave™ D-EECT-equipment. The total order value is EUR 40,000.
Payment will be made through a payment plan which runs on 18 months. In addition to the hospital, six of its doctors are co-investors in the IQWave™. This is a business model that the hospital is using to increase the recruitment of patients for new investments, something that we at ChemoTech hope will increase the number of patients that will be offered our technology, says Mohan Frick, CEO at ChemoTech.
The delivery is expected to take place at the end of March 2018.
I am delighted with this decision of Baypointe to invest in the IQWave™ D-EECT-equipment and look forward to having more hospitals to join their ranks soon, commented Conrad Perreras, Country Manager at ChemoTech in the Philippines.
For more information, please contact:
Mohan Frick, CEO
Tel: +46 (0)10-218 93 03
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Wednesday Febuary 7th 2018 at 08.30 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on NASDAQ First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.